SalesTrax.com Research: Sanofi-Aventis

Articles found below have been submitted through various PR and news sources and don’t necessary reflect the views of SalesTrax or its employees.


Pharmaceutical Business Review

2009-09-18 12:04
Sanofi-Aventis Completes Acquisition Of Merck's Interest In Merial
Acquisition is expected to be accretive to sanofi-aventis' adjusted net income from the first year

2009-09-18 04:04
Sanofi-aventis Receives Complete Response Letter From FDA
Eplivanserin, a potential treatment for patients with chronic insomnia

2009-09-15 04:04
Sanofi-Aventis Reports Results Of Phase II Study With Teriflunomide
Teriflunomide, a novel orally available immunomodulatory therapy for multiple sclerosis

2009-09-01 04:04
Sanofi-aventis Reports Positive Results For Otamixaban
Results demonstrate, Otamixaban substantially reduced complications of invasive management of acute coronary syndromes

2009-08-12 04:03
Hospira Launches Oxaliplatin Injection In US
Oxaliplatin injection, a generic version of Sanofi-Aventis' Eloxatin, is indicated for adjuvant treatment of stage III colon cancer

2009-07-31 08:03
Sanofi-aventis To Acquire Merck's Interest In Merial
Acquisition values Merial on the basis of 3.0 x 2008 sales and 10.2 x 2008 earnings before interest and taxes

2009-07-30 04:03
Sanofi-aventis' Q2 Net Sales Up 11.2%
Net sales for the first half increases by 6.7%

2009-07-30 04:03
Sanofi-aventis Receives FDA Approval For Sculptra Aesthetic
Sculptra Aesthetic, for the correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles

2009-07-29 04:03
Sanofi-Aventis' Multaq Now In US
To reduce cardiovascular hospitalization in patients with atrial fibrillation (AF) or atrial flutter (AFL)

2009-07-16 04:03
Sanofi-Aventis Provides Expert Report On Lantus
Significant methodological limitations and shortcomings in all four manuscripts

2009-07-15 12:03
Sanofi-Aventis Provides Expert Statement On Lantus
Significant methodological limitations and shortcomings in all four manuscripts, said experts

2009-07-06 12:03
Sanofi-aventis Unveils Lantus Study Results
The study showed long term safety of Lantus as compared to NPH

2009-07-02 16:04
Sanofi-aventis Receives FDA Approval For Multaq
Multaq to treat patients with atrial fibrillation or atrial flutter

2009-07-01 12:04
Sanofi-Aventis Presents New R&D Model Project
Model aims to transform R&D and increase innovation

2009-07-01 04:04
Sanofi-Aventis Presents New R&D ModelProject
Model aims to transform R&D and increase innovation

2009-06-12 12:04
Sanofi-Aventis, Regeneron Provides Phase-II Results For Aflibercept
Patients receiving aflibercept experienced a statistically significant improvement

2009-06-09 04:03
Sanofi-Aventis To Purchase Diabel Manufacturing Facility In Frankfurt
Scope of acquisition includes buildings, equipment, machinery and some existing contracts

2009-06-08 12:04
Sanofi-Aventis' Lantus Witnesses Positive Results
A1C reductions, with many patients achieving the target A1C of less than 7%.


Forbes.com

2009-12-21 20:00
Sanofi's Allegra Gambit
By buying Chattem, Sanofi-Aventis gets skilled marketers who can launch its allergy drug in the lucrative U.S. over-the-counter market.

2009-10-30 04:00
Living Without Blockbusters
Sanofi-Aventis' Christopher Viehbacher is slashing R&D and moving into emerging countries.

2009-07-16 16:02
Dismissing An Insulin-Cancer Link
A panel convened by drugmaker Sanofi-Aventis cautions patients not to stop taking insulin.